5 completed. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 3 |
Follow Vacc-4x: new trials by email Literature Review of Vacc-4x trials Research Report on Vacc-4x
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir Romidepsin, Vacc-4x, rhuGM-CSF - HIV I Infection | Phase 1 / Phase 2 | Completed | Bionor Immuno AS | 26 | 2014-03-01 | 2017-03-01 |
| Re-boosting of HIV-1 Infected Subjects With Vacc-4x Vacc-4x - HIV-1 Infection | Phase 2 | Completed | Bionor Immuno AS | 33 | 2012-12-01 | 2017-03-06 |
| Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) Lenalidomide, Lenalidomide placebo, Vacc-4X - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Bionor Immuno AS | 36 | 2012-09-01 | 2017-03-08 |
| Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant Vacc-4x low dose, Vacc-4x medium dose, Vacc-4x high dose - HIV Infection | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 24 | 2011-11-01 | 2012-06-20 |
| Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV Vacc-4x, Sterile water - HIV I Infection | Phase 2 | Completed | Bionor Immuno AS | 137 | 2008-08-01 | 2017-02-23 |
Infections (2) · HIV Infections (1)
Bionor Immuno AS (4) · Oslo University Hospital (1)
Germany (3) · Italy (2) · Spain (2) · United Kingdom (2) · United States (2) · Denmark (1) · Norway (1)
Dag Kvale, Professor/MD (1) · Kim Krogsgaard (1) · Richard Pollard, MD (1) · Vidar Wendel-Hansen, Dr. med (1)
PMID 24525316, PMID 25398137, PMID 26379282, PMID 27658863, PMID 30699178